In Depth 11 Oct 2021
A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology
CAR-T therapy has been hailed as a cure for cancer, but what really is this ‘miraculous technology’ and what can…
Celgene
- Latest Posts
News and Trends 28 Aug 2019
Celgene and Immatics Sign Deal Worth Over €1.35B to Develop Cancer Immunotherapies
The US company Celgene has obtained options to three cancer immunotherapy programs from the German biotech Immatics in a deal…
News and Trends 21 Mar 2019
Celgene and Exscientia Sign the Largest Deal in AI for Drug Discovery
In a deal with €22M paid upfront and undisclosed “substantial milestones and royalties,” Exscientia will use its artificial intelligence technology…
News and Trends 25 Jan 2019
Swiss-Italian Biotech Bags Antibody Deals with Three Big Pharma
The Swiss-Italian company Philogen has announced three different partnerships with Novartis, Celgene, and Janssen to develop new forms of immunotherapy…
ADVERTISEMENT
News and Trends 23 Jan 2018
Another Huge Acquisition Sees CAR-T Stocks Jump – Except for Celyad
Most CAR-T stocks rose on the news that Big Biotech Celgene has plans to acquire Juno: Cellectis rides the wave…
News and Trends 16 Oct 2017
Interview: On the Future of iPS Cells and why Partnering is so Important in this Field
In our first part of the interview with Dr David Hallett, Executive Vice President at Evotec, we discussed the uniqueness…
News and Trends 19 Dec 2016
Evotec closes the year partnering with Celgene to treat Alzheimer’s
Evotec is closing a fantastic financial year with another top-level partnership; Celgene has decided to trust in its iPSC platform…
News and Trends 30 Jun 2016
11 Hot Companies to Meet this Year at BioSpain
Spain has a lot of great stuff – paella, tapas, siesta! But how is Spanish biotech doing? With BioSpain 2016 approaching, we…
News and Trends 4 Nov 2015
Transformational deals that shaped the Biotech industry in 2015 #BIO-Europe 2015
The Biotech industry relies a lot on partnering and deals. And 2015 has already been an active year. This was…
